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Induced pluripotent stem cells in hematology: current and future
applications
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1,6, G Amabile
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4, DG Tenen
2,5 and M Pistello
4
Reprogramming somatic cells into induced pluripotent stem (iPS) cells is nowadays approaching effectiveness and
clinical grade. Potential uses of this technology include predictive toxicology, drug screening, pathogenetic studies and
transplantation. Here, we review the basis of current iPS cell technology and potential applications in hematology,
ranging from disease modeling of congenital and acquired hemopathies to hematopoietic stem and other blood cell
transplantation.
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INDUCED PLURIPOTENT STEM CELLS
Stem cells, generally deﬁned as cells able to undergo self-renewal by
asymmetric cell division, can be classiﬁed according to potency.
Pluripotent cells, able to differentiate into any of the three germ
layers, can be isolated from blastocysts (embryonic stem (ES) cells) or
generated by reprogramming of adult somatic cells (induced
pluripotent stem (iPS) cell)
1 (Figure 1). Despite that ES cells represent
the most promising type of cells for scientiﬁc and clinical
applications, their use poses a set of concerns (Table 1).
The core technology of iPS cell generation consists of ectopic
expression of master reprogramming factors (RFs). The iPS cells
have been generated for the ﬁrst time from murine ﬁbroblasts in
2006 by Takahashi and Yamanaka
2 using the transcription factors
Oct4, Klf4, Sox2 and c-Myc (OKSM). In 2007, the teams of
Yamanaka
3 and Thomson
4 successfully reprogrammed primary
human ﬁbroblasts using the OKSM cocktail
3 and Klf4, Oct4, Sox2
and LIN28,
4 respectively. Many groups have been able to avoid
use of the proto-oncogene c-Myc because of transformation
concerns
5,6 by replacing it with less dangerous genes.
7,8 In order
to overcome the low transfection efﬁciency of primary cells,
several retroviral or lentiviral vectors (LVs) have been used to
introduce RFs into cells. However, the insertional mutagenesis
associated with these vectors still represents a major downside of
this type of approach.
9 Vector integration raises additional
concerns related to the stable permanence of the RFs.
Prolonged and uncontrollable duration of RF expression, as well
as RF silencing and spontaneous reactivation, have been shown to
affect iPS cell biological properties both in vivo and in vitro.
10,11 For
these reasons, many efforts have been made to increase the safety
of delivery approaches and to provide tightly RF controllable
expression systems. To date, a wide array of delivery systems have
been tested ranging from adeno-associated vectors whose
parental viruses integrate in ‘safe harbor’ genomic sites
12 to
nonintegrating viral vectors (for example, Sendai virus) and to
inducible vectors in which RF expression is tightly regulated by
external switches.
13
IMMUNOGENICITY OF IPS CELL-DERIVED SOMATIC CELLS
Although iPS cells are ideal for patient-tailored treatments
for genetic disease, their derivatives could be used to
treat diseases in non-histocompatible recipients. Apart from
containing necrotic culture debris or induced vasculature,
iPS cell products do not contain donor antigen-presenting
cells, and hence in principle they would not be able to
induce direct allorecognition. This property makes iPS cells
immunogenic only through recipient antigen-presenting cells: a
minor ‘indirect pathway’ leading to chronic but not acute
rejections. As soon as more complex tissues will be generated,
the possibility of having cells with antigen-presenting capacity
would signiﬁcantly increase. Until then, human leukocyte
antigen (HLA) compatibility remains a suitable objective, and
the creation of regional ‘haplobanks’ of iPS cells has been
encouraged.
14
Few cell types differentiated from iPS cells appear less
immunogenic than their native counterpart. For example,
human iPS cell-derived hematopoietic progenitor cells induce
T-cell anergy in in vitro-generated alloreactive CD8
þ Tc e l l s ,
and are not susceptible to natural killer (NK) cell cytotoxicity.
15
This assumption cannot be considered universal, as
demonstrated by the increasing immunogenicity of allogeneic
cardiomyocytes derived in vivo from iPS cells.
16 Furthermore,
abnormal gene expression in speciﬁc differentiated cell
types derived from iPS cells is able to induce T cell-dependent
immune response in syngeneic recipients.
17 Despite these
ﬁndings, Araki et al.
18 f o u n do n l yal i m i t e di m m u n o g e n i c i t y
of transplanted cells differentiated from iPS and ES cells.
Therefore, the immunogenicity of therapeutically valuable
cells derived from patient-speciﬁc iPS cells should be
evaluated before any clinical application. Indeed, OCT4-speciﬁc
T cells can be readily detected in freshly isolated T cells from
480% healthy donors, 35% of patients with newly diagnosed
germcell tumors and nearly 100% of these patients after
chemotherapy.
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Transgenic mice models have been generated in the attempt to
recapitulate a disease phenotype; however many of these models
are, in the best scenario, only similar to the human disease and
often reﬂect incompletely the speciﬁc and relevant pathogenetic
mechanisms. In particular, as iPS cells represent an early stage of
disease, the establishment of in vitro differentiation models
recapitulating speciﬁc cell-type differentiation would be relevant
for dissecting pathogenetic events responsible for disease
initiation and progression.
Understanding diseases affecting principally the bone marrow
(BM) is quite limited if researchers have to only rely mostly on
peripheral blood leukocytes. Speciﬁc hemopathies in which tissue
samples are scarce, for example, idiopathic myeloﬁbrosis or
aplastic anemia, represent an important challenge. Patient-derived
iPS cells hold promise for understanding the molecular pathways
involved in disease through the establishment of ‘the disease in a
dish’. In particular, as iPS cells have the potential to differentiate
into every cell of the hematopoietic system, cell types relevant for
a speciﬁc disease can be generated recapitulating in vitro a
speciﬁc-disease environment. This approach could lead to the
identiﬁcation of new genetic and epigenetic aberrations including
environmental stress inducers that might represent a precipitating
event during disease onset and otherwise not detectable.
INHERITED BM FAILURE SYNDROME
Inherited BM failure syndromes are a heterogeneous group of
genetic disorders characterized by BM failure, congenital abnorm-
alities and an increased risk of generating malignant diseases. The
representative diseases with involvement of all hematopoietic
lineages are the Fanconi anemia and the dyskeratosis congenita.
Diamond–Blackfan anemia (DBA) is, instead, a disease affecting
exclusively the erythroid lineage. To date, the only available
Table 1. Advantages and disadvantages of iPS cells vs other types of pluripotent stem cells (see text for references)
Pluripotency Preservation of sex-
speciﬁc gene imprinting
Tissue-speciﬁc
epigenetic
memory
Strength of selection - clonal
variability of nuclear reprogramming
Genetic (CNV)/
epigenetic errors
Derivation
frequency
ES þþþþ þþþþ þ þþþþ þ þþþþ
ntES þþþ þþ þþ þþþ þþ
pES þþ Female only þþþ þþ þþ þþþ
ahES þþ Male only þþþ þþ þþ þþþ
iPS þþ þ þþþþ þ þþþþ þ/
þþþþ
Abbreviations: +, low; þþ, moderate; þþþ, high; þþþþ, very high; ahES, androgenetic haploid ES cells; CNV, copy number variation; ES cell,
embryonic stem cell; iPS cell, induced pluripotent stem cell; nt, nuclear transfer ES cells; pES, parthenogenetic ES cells.
enucleated oocyte
somatic cell
donor nucleus
blastocyst
with inner
cell mass
(ICM)
sperm cell
donor nucleus
fertilized oocyte
embryonic
stem (ES) cells
: banks
parthenogenetic
ES (pES) cells
nuclear transfer ES (ntES) cells
(CLONING) (derived in mice, cattle,
monkeys (Byrne JA, Nature, 2007),
and humans (Tachibana M, Science,
2013); HLA-matched, remaining
maternal mitochondrial antigens
present in oocyte cytoplasm.
Requires abundant source of
altruistic egg donors (ethical??) or
ESC-derived oocytes (Hayashi K,
Science, 2012) 
androgenetic
haploid ES
(ahES) cells
induced pluripotent stem (iPS)
cells : HLA-matched
(Takahashi, Cell, 2006)
not able to develop
into viable offspring uniparental zygotes
nt-embryo
￿RF delivery : OCT4+other TF
(viral vectors, episomal vectors, proteins, mRNA, miRNA)
￿ Epigenetic inducers :
(small chemicals, acidic bath)
haploid duplicated homozygous
genome→ emergence of recessive
traits, NK cell-mediated immune
rejection unless you select a subset
of pESC that have undergone
crossing-over events in HLA region
during meiosis
sperm cell 
fertilization
androgenesis
parthenogenesis
SCNT
electrical
discharge
somatic cell
oocyte
Figure 1. Different strategies to generate pluripotent stem cells.
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allogeneic hematopoietic stem cell (HSC) transplantation, even
though most patients do not have fully HLA-matched donor, and
those who do still have the risk of morbidity and mortality.
Low reprogramming efﬁciency of patient ﬁbroblasts has been
described in inherited disorders associated with activated p53,
such as Diamond–Blackfan anemia,
20 Fanconi anemia
21 and ataxia
telangiectasia.
22 Transgenic expression of the implicated genes
has been shown to correct the phenotype of hematopoietic cells,
but in many cases gene therapy attempts have failed mainly
because of the low efﬁciency of gene targeting and inadequate
selection of real HSC population. Alternatively, gene editing of
somatic cells followed by reprogramming to iPS cells and
subsequent expansion and redifferentiation into HSCs can be
exploited to overcome the low gene targeting efﬁciency.
23
HEMOGLOBINOPATHIES
Hemoglobinopathies are genetic inherited conditions that origi-
nate from the lack or malfunction of the hemoglobin protein. The
severe anemia combined with the complications associated with
the most aggressive subtypes raises the necessity for a cure to
restore the hemoglobin function. Routine therapies for these
conditions, namely transfusion and iron chelation, have signiﬁ-
cantly improved the quality of life of the patients over years,
despite that the pathogenetic mechanism of this group of disease
remains largely unknown. A curative option is the allogeneic HSC
transplantation. However, this approach is limited by both the
availability of suitable donors and by the graft-versus-host disease.
Gene therapy offers an alternative approach to cure hemoglobi-
nopathies by the direct recovery of the hemoglobin function via
globin gene replacement. In the past two decades, gene transfer
tools based on LV development have been signiﬁcantly improved
and proven to be curative in several animal models for sickle cell
disease (SCD) and thalassemia.
24
THALASSEMIAS
The b-thalassemias are one of the most prevalent inherited
disorders worldwide. They are caused by over 200 different types
of either point mutations or deletions of nucleotides in b-globin
gene, resulting in reduced, abnormal or no synthesis of b-globin
chains. Patients affected by b-thalassemias have severe anemia
and a shortened lifespan. Compound b
E/b
0-thalassemia is the
most common form of severe thalassemia in Southeast Asian
countries and their diasporas. The b
E-globin allele bears a point
mutation that causes alternative splicing. The abnormally spliced
form is noncoding, whereas the correctly spliced mRNA expresses
a mutated b
E-globin with partial instability. When this is
compounded with a nonfunctional b
0 allele, a profound decrease
in b-globin synthesis is observed, and approximately half of
b
E/b
0-thalassemia patients are transfusion dependent. Gene
therapy for b-thalassemia is particularly challenging given both
the requirement for massive hemoglobin production in a lineage-
speciﬁc manner and the lack of selective advantage for corrected
HSCs. To date, only one adult with transfusion-dependent
b
E/b
0-thalassemia major was transplanted with globin LV-trans-
duced autologous CD34
þ cells. This patient (who is still transfusion
independent at 4.5 years of follow-up
25) showed a semidominant
myeloid-biased cell clone bearing a globin lentivirus within the
HMGA2 gene. The clonal dominance that accompanies therapeutic
efﬁcacy may be coincidental and stochastic or result from a hitherto
benign cell expansion caused by dysregulation of the HMGA2 gene
in stem/progenitor cells.
26
A relevant issue to hemoglobinopathies is whether persistence
of fetal hemoglobin or embryonic–fetal–adult globin class switch-
ing can occur in vivo after transplantation with human iPS cell-
derived HSCs. LV-transfected iPS cell-derived HSCs were compared
with their LV-transfected natural isogenic somatic counterparts.
In particular, NSG immunodeﬁcient mice transplanted with the
corrected cells showed an embryonic to fetal and a partial fetal to
adult globin class switching. This ﬁnding suggests that the
b-globin gene transfer is likely necessary for iPS cell-based therapy
of the b-hemoglobinopathies.
25 If HSCs will be safely derived from
iPS cells, it is envisaged that patient-speciﬁc autologous iPS cells
will also be routinely generated for patients affected by
hemoglobinopathies and HSCs obtained by in vitro differentiation.
In fact, HSCs derived from iPS cells may be corrected by gene
editing (for example, transcription activator-like effector nucleases
(TALENs)
27) or modiﬁed by lentiviral transfer carrying a therapeutic
gene. A screening to assess viral integration in chromosomal areas
of lower genotoxic potential is likely to become an important step
for this kind of approach. An alternative to b-globin gene transfer
might be the erythroid-speciﬁc knockdown of BCL11A by means of
small hairpin RNA, thereby forcing g-globin expression and
b-globin downregulation.
The a-thalassemia major (hydrops fetalis) has also been
corrected in transgene-free iPS cells using zinc-ﬁnger nuclease-
mediated insertion of a globin transgene in the AAVS1 site of
human chromosome 19. Homozygous insertion of the best of the
four constructs tested led to a complete correction of globin chain
imbalance in erythroid cells differentiated from the corrected iPS
cells.
28
SICKLE CELL DISEASE
In the majority of SCD patients, the mutation of A4T (also known
as b
A to b
s mutation) in both alleles of the b-globin (HBB) gene
changes codon 6 from Glu (GAG) to Val (GTG), resulting in a
defective form of adult hemoglobin. An ideal iPS cell-based gene
therapy for SCD would require both precise correction of disease-
causing mutation and a complete switching from fetal-type globin
to adult-type globin.
Although SCD was one of the ﬁrst described molecular diseases,
the goal for treating this monogenic disorder using gene therapy
approaches has not been fully accomplished in humans.
29 Gene
correction of b
s in mouse ES cells by homologous recombination
(HR) has previously been reported.
30 Similarly, correction of the b
s
mutation in murine iPS cells derived from a humanized SCD
mouse model, followed by successful transplantation of
differentiated hematopoietic cells into isogenic mice, has been
applied to cure SCD phenotypes.
31 Zou et al.
32 demonstrated a
site-speciﬁc gene correction of the silent HBB gene correction in
human patient-speciﬁc iPS cells. Such corrected iPS cells could be
redifferentiated in red blood cells (RBCs) expressing 25–40% of the
wild-type b
A allele.
TRANSPLANTATION OF GENETICALLY UNEDITED,
IPS CELL-DERIVED HSCS
HSCs derived from BM, umbilical cord
33 and mobilized
34 or
nonmobilized
35 peripheral blood have been successfully used as a
source for iPS cell generation. On the other hand, iPS cells obtained
from different somatic cell types of humans and nonhuman
primates
36 can be successfully redifferentiated to HSCs (Figure 2).
To date, there are at least three efﬁcient ways to differentiate
HSCs from iPS cells.
37 (1) Coculture with OP9 cells, a murine
mesenchymal stem cell line established from newborn B6C3F1
osteopetrotic mouse calvaria not producing functional
macrophage colony-stimulating factor.
38 Coculture of OP9 cells
with mouse ES cells has been used to develop a preferential
differentiation induction system of pluripotent cells into
hematopoietic cells other than monocytes. Although the use of
mouse stroma provides a barrier to clinical translation, this
barrier might be overcome if a master cell bank is produced.
39
(2) Transduction of iPS cells with Lhx2, a LIM-homeobox
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40 (3) Dissociation of teratoma-generated
immunodeﬁcient mice. Our group recently showed that human
iPS cells differentiate within teratomas generating functional
myeloid and lymphoid cells. Similarly, HSCs can be isolated from
teratoma parenchyma and reconstitute a human immune system
when transplanted into NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ
immunocompromised (NSG) mice.
41 Suzuki et al.
42 reported that
human iPS cell-derived HSCs migrate from teratomas into the
murine BM and their intravenous injection into irradiated
recipients resulted in multilineage and long-term reconstitution
of the hematolymphopoietic system in serial transfers. Using
this in vivo generation system, X-linked severe combined
immunodeﬁciency mice can be treated by HSCs derived from
gene-corrected clonal iPS cells. It should also be noted that neither
leukemia nor tumors were observed in recipients after
transplantation of iPS cell-derived HSCs.
42
Other strategies have been successfully implemented with ES
cells, and could theoretically be adapted to iPS cells. (1) Dissociation
of human embryoid body (EB) at days 7–10;
43 however, human ES
cell-derived HSCs had limited proliferative and migratory capacity
compared with somatic HSCs.
44 The traditional ‘feeder-free’
system of EB-mediated differentiation of human ES cells/iPS cells
may be utilized, although it tends to be more variable in
differentiation into hematopoietic progenitor cells. Alternative
methods such as ‘spin-EBs’ aggregate undifferentiated human ES
cells through centrifugation
45 in the absence of murine stroma.
46
(2) Coculture with monolayers of cells derived from mouse
aorta-gonads-mesonephros and fetal liver, or with stromal cell lines
derived from these tissues.
47 (3) Ectopic expression of CDX4 and
HOXB4 expression.
48 (4) Culture with MEDII (medium conditioned by
HepG2 cells, a human hepatocarcinoma cell line).
49
Modern HSC mobilization drugs (granulocyte colony-stimulat-
ing factor and CXCR4 antagonists) make access to this type of cells
particularly easy. From this point of view, transiting through the
pluripotent status in order to achieve HSCs seems to be a
complication. However, differentiation of HSCs from iPS cells can
be particularly useful in the presence of congenital or acquired
settings where HSC harvest is poor (for example, idiopathic
myeloﬁbrosis or aplastic anemia) or whenever expansion to large
numbers is required. As previously stated, apart from reconstitut-
ing hematopoiesis, human iPS cell-derived HSCs also retain the
unique and interesting ability to induce T-cell anergy in in vitro-
generated alloreactive CD8
þ T cells.
15
TRANSPLANTATION OF IPS CELL-DERIVED, GENETICALLY
ENGINEERED AUTOLOGOUS HSCS IN GENETIC HEMOPATHIES
Genetic engineering in inherited hemopathies can be performed
directly on autologous HSCs provided that they are available and
prone to transfection and transduction. As both conditions are
difﬁcult to achieve,
50 iPS cell technology may result in a valuable
alternative.
51
Gene manipulation has been performed on iPS cells with
several technologies: (1) suppression of expression, either
transient or sustained,
52 of disease-related genes in patient-
speciﬁc iPS cells by RNA interference; (2) gene knockout;
53 (3) HR
that can be used for phenotypic correction of loss-of-function
mutations,
54 and correction or replacement of underlying disease-
causing mutations at the endogenous loci. Differently to
conventional gene therapy approaches, HR ensures that the
corrected gene will be expressed in an appropriate temporal and
tissue-speciﬁc manner under the regulation of endogenous cis-
elements. HR can be pursued with several and constantly
improving methods such as: (1) zinc-ﬁnger nucleases;
55 (2)
TALENs; TALENs efﬁciently recognize and cleave any given DNA
sequences and, compared with zinc-ﬁnger nucleases, exhibit
lower unspeciﬁc cleavage, with a reduced nuclease-associated
cytotoxicity;
56 (3) clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated (Cas) systems in bacteria and
archea use short RNA to direct degradation of foreign nucleic: this
activity has been exploited for gene targeting in iPS cells,
57,58 even
at multiple loci simultaneously;
59 and (4) helper-dependent
adenoviral vectors.
60
Following HSC expansion at a suitable dose and, if applicable,
ex vivo or in vivo selection for corrected/modiﬁed cells,
appropriate pretransplantation conditioning (myeloablation) of
the patient can eventually be applied before intravenous or
intrabone infusion of HSCs.
TRANSPLANTATION OF DIFFERENTIATED BLOOD CELL TYPES
Anucleated cells
Because of short half-life and absence of nucleus, such cells spare
investigators and patients from risks of oncogenicity, and are
hence the most immediate candidates for clinical trials. This
category includes most likely mature RBCs and platelets. An
efﬁcient screening to separate accurately all the anucleated cells
from the nucleated counterpart appears to be a limiting step for
this kind of application.
RBCs are unique, highly specialized and the most abundant cells
in humans. The primary function of RBCs is transportation of the
respiratory gases O2 and CO2. Meanwhile, RBCs are also the main
antioxidant reservoir for the whole body. Blood transfusion is a
common procedure in modern medicine, and it is practiced
throughout the world; however, many countries report a less than
sufﬁcient blood supply. Even in developed countries where the
supply is currently adequate, projected demographics predict
insufﬁciency in this supply as early as 2050. Once alloimmuniza-
tion occurs, such patients require RBCs from donors with a
different blood group antigen combination, making it a challenge
to ﬁnd donors after every successive episode of alloimmunization.
Alternative blood substitutes such as synthetic oxygen carriers
have so far proven unsuccessful.
61 Transfusing iPS cell-derived
RBCs (safer than transplanting genetically engineered iPS cell-
derived HSC) suffers from two major limitations: short half-life and
need for repeated, life-long transfusions. Nevertheless, iPS cell-
derived RBCs have the potential to alleviate shortages and
produce pathogen-free O Rh-negative ‘universal donor’ RBCs.
The major limitations for translating iPSC-derived RBCs into clinic
are: (1) inefﬁcient enucleation, (2) difﬁcult switching to adult-type
(b) globin form and (3) the possibly insurmountable number of
RBCs (10
12) needed to generate one unit.
fibroblasts
PB HSCs
MAIT cells MSCs
B lymphocytes
T lymphocytes
monocytes
dendritic cells
CB HSCs
BM HSCs
iPS cells
Figure 2. Summary of blood cell types successfully used as a source
for iPS cell generation, and of blood cells successfully redifferen-
tiated to blood cells to date (see text for references).
The iPS cells in hematology
D Focosi et al
4
Blood Cancer Journal & 2014 Macmillan Publishers LimitedThe iPS cell-derived autologous platelets have potential to
alleviate supply shortages because of high demand and limited
shelf-life. Production of pathogen-free O universal donor platelet
concentrates with negligible isoagglutinin titers would be the ideal
aim. The iPS cell-derived platelets have been generated
62 and will be
soon tested in clinical trials (Advanced Cell Technologies). The main
methods are handpicking ES sacs with two-step stroma coculture or
HB method with one-step stroma coculture. The major limitation is
reliance on stroma and inefﬁciency/poor yield in megakaryocyte to
platelet differentiation step.
Monocytes, monocyte-derived dendritic cells (DCs) and
macrophages
Current methods for generating human primary macrophages
vary in cell yield, purity and activation status, often resulting in
conﬂicting and difﬁcult to interpret results. The circulating mono-
cytes are heterogeneous and vary in size, granularity, morphology
and protein expression proﬁle. Several different monocyte subsets
have been characterized.
63 Moreover, the method of isolation
inﬂuences the properties of differentiated macrophages and
monocyte-derived DCs. The primary human monocytes have a
limited potential for proliferation in vitro and are difﬁcult to
transfect. Thus, development of new approaches to produce a
homogenous population of macrophages is of large interest.
Furthermore, the phagocytic activity of these cells limits the ability
for additional genetic manipulation. Genetically modiﬁed
macrophages differentiated from human iPS cells can serve as a
useful model for understanding the etiology of, for example,
macrophage-tropic HIV-1 disease, and facilitating the
development of novel therapeutic interventions.
Because of HLA restriction of the adaptive immune response, it
was soon realized that the unavailability of human ES cells
genetically identical to the patients was a problem in the clinical
application. Genetic modiﬁcation of ES cell-derived DCs, and
laborious modiﬁcation of the b2m or TAP gene, has been
attempted to solve the problem of HLA class I allele mismatch
between human ES cells and the recipients to be treated.
64
Theoretically, the histocompatibility issue may be resolved by
autologous iPS cell-derived DCs. In fact, DCs derived from xeno-
free human iPS cells
65 have been shown to be fully functional.
However, animal models are needed to test the in vivo efﬁcacy
and safety of this procedure.
The monocyte-derived DCs have been widely used in cancer
immunotherapy showing signiﬁcant donor-to-donor variability
and low capacity for the cross-presentation of tumor-associated
antigens to CD8
þ T cells. These fundamental properties reside
only in CD141
þXCR1
þ DCs that are present only in trace in
peripheral blood and for this reason are not suitable for clinical
application. The ability to generate a potentially unlimited source
of DCs from iPS cells offers the possibility of harnessing their
capacity for cross-priming cytotoxic T lymphocytes inducing a
tumor-speciﬁc immune response.
66
Assuming allogeneic iPS cells will be used, once a clone of TAP-
or b2m-deﬁcient human iPS cells is established, a premade library
of clones expressing various types of HLA class I can be generated
by the introduction of various HLA class I genes. Currently, TAP2-
deﬁcient iPS cell clones have been generated using zinc-ﬁnger
nucleases,
67 and other could be achieved from patients with type I
bare lymphocyte syndrome caused by mutation of the TAP1 or
TAP2 gene. This will not solve the issue of HLA class II antigen
matching.
NK lymphocytes
The natural lifespan for NK cells in the human body is B2 weeks.
Only few human permanent NK-like cell lines are available for
research, mostly derived from NK cell leukemia or lymphoma
patients, and hence lacking important features of normal NK cells.
Furthermore, several of these NK-like cell lines are latently infected
with Epstein–Barr virus (EBV), and the contribution of viral
effectors to cell proliferation and survival has not been studied;
only recently in vitro growth transformation of functional human
NK cells by Herpesvirus saimiri has been reported.
68
NK lymphocytes are capable of killing cells with missing self
(that is, HLA class I expression). NK cells have been generated from
iPS cells and have the potential application in both cancer
therapy
69 and infectious diseases.
70 Interleukin-2 is generally used
to expand effector cytotoxic T or NK cells in vitro and in vivo, and it
also promotes the expansion of T regulatory cells expressing the
interleukin-2 receptor b-chain CD25. As T regulatory cells are able
to directly suppress both T- and NK-cell responses, the therapeutic
effect of effector cells is limited. In addition, it is not completely
clariﬁed why NK cell-based immunotherapy is effective for acute
myeloid leukemia but not for other hematological or solid
malignancies. Genetic engineering is difﬁcult to achieve in
primary peripheral blood NK cells, whereas high-efﬁciency
genetic modiﬁcation is routinely feasible in human iPS cell-
derived NK cells that result in high effectiveness in animal models.
Strictly considering the cell number, it seems feasible and
reasonable to generate a signiﬁcant amount of human iPS cell-
derived NK cells for adoptive immunotherapy (B10
7–10
8 NK cells
per patient). Major limitation is reliance on two steps of stroma
coculture, and the need for sorting of rare CD34
þCD45
þ cells
may hinder clinical scale-up.
The fact that NK cells express all of the components to signal
through the T-cell receptor (TCR) makes them particularly suitable
to be used as a platform to utilize ectopic TCR expression. This
approach seems to be particularly important because of lack of
competition for TCR binding between endogenous and exogen-
ous a/b subunits.
T lymphocytes
The iPS cells, by rejuvenating the original adult somatic cell,
represent an interesting technology to achieve large doses of
functional autologous antigen-speciﬁc T lymphocytes for immu-
notherapy.
71–73 If the TCR speciﬁcity is too rare or absent in the
patient, autologous polyclonal lymphocytes can eventually be
cleared of their endogenous TCR and then transfected with a
chimeric antigen receptor.
72 Figure 3 represents the potential
approaches to achieve large doses of functional, antigen-speciﬁc
autologous effector T lymphocytes, avoiding off-target toxicity.
74
T cells are usually derived from iPS cells through the OP9
coculture system or by the way of teratoma formation.
41 The OP9
cell line ectopically expressing the Notch ligand Delta-like 1 (Dll1)
or Dll4 (OP9-DL1 and OP9-DL4, respectively) gains the ability to
recapitulate thymus-like function, supporting T-cell differentiation
of both murine and human progenitors.
T lymphocytes with invariant a-chain
T lymphocytes with invariant a-chain act as innate T lymphocytes
and serving as a connection between the innate and acquired
immune systems. Both type I natural killer T (NKT) cells or invariant
NKT (iNKT) cells)
75 and mucosa-associated invariant T cells
76 have
been generated from iPS cells. To date, there is no report about
germline-encoded, mycolyl-reactive T cells yet.
This cell population seems to be important for the defense
against mycobacteria, fungi and cancer. In fact, once iNKT cells are
activated by a-GalCer-pulsed DCs, they are capable to eliminate
both MHC
  and MHC
þ tumor cells. Both these types of tumor
cells are simultaneously present in patients, and at present iNKT
cells are the only known cell type capable to eliminate them.
Apparently, two-thirds of patients were ineligible for this adoptive
therapy because of the limited number of iNKT cells in their
bodies.
75
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ﬁrst time will likely pave the way to adoptive cell therapies.
B lymphocytes
Despite initial issues, few reports focusing on the generation of iPS
cells from B cells have been published. In parallel, it has been
shown that iPS cells undergo lymphoid differentiation when
cocultured with OP9 stroma cells
77 or through intra-teratoma
lymphopoiesis.
41
Large collections of EBV-immortalized B-cell lines (EBV-B) from
patients affected by various diseases have been maintained in a
large number of institutions. These EBV-B cells can be an excellent
resource for disease-speciﬁc iPS cell generation and banking for a
variety of human diseases, especially for those patients with rare
diseases whose tissues are no longer available, except as
preserved EBV-transformed B cells.
78
Mesenchymal stem cells (MSCs)
MSCs have been considered safe as they do not show tumor
formation after transplantation and have been widely proven
efﬁcacious in preclinical and clinical studies for cardiovascular
and neurodegenerative diseases, graft-versus-host disease and
autoimmune disease. Systemic administrations of allogeneic
MSCs (for example, Prochymal or MultiStem) do not cause any
adverse effects, in part because of immunomodulatory effects.
Genetically manipulated MSCs may also serve as cellular
therapeutics as these cells can be used as targeted drug
delivery vehicles.
MSCs from different tissues represent an interesting source for
iPS cell generation.
79 On the other side, MSCs have been
derived from iPS cells and show preserved regenerative
80 and
immunomodulatory
81 functions. Identiﬁcation and utilization of
genetically modiﬁed MSCs, having a ‘safe harbor’ integration, is
restricted because of the limited lifespan of primary MSCs in vitro.
Aging, moreover, signiﬁcantly reduces the survival and
differentiation potential of BM-MSCs. In contrast, using human
pluripotent stem cells (human ES cells or iPS cells) can generate
indeﬁnitely fresh MSCs. Furthermore, genetically engineered MSC
clones could be generated from iPS cells after an accurate
screening for a vector integration sites and cells with safe harbor
integrations potentially expanded nearly indeﬁnitely.
82
CONCLUSIONS
The advent of iPS cell technology produced an important
milestone in hematology. The availability of patient-speciﬁc
pluripotent stem cells will undoubtedly improve disease model-
ing, drug development and will pave the way to autologous cell
therapy for many monogenic and acquired diseases. Many biotech
companies are nowadays focused on iPS cells in order to generate
novel effective therapeutic molecules. Currently, biotech compa-
nies are already signiﬁcantly engaged and invested in the
development and commercialization of iPS cells. It has been
estimated that the iPS cell market is projected to grow to US$ 1
billion by 2016.
83 Provided regulatory authorities will not pose
limits to iPS cell research,
84 the growing engagement of all
pharmaceutical companies appear today a crucial step for
translating iPS cells from bench to bedside in the coming years.
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